GLAXF:OTO-GlaxoSmithKline Plc (USD)

COMMON STOCK | Drug Manufacturers - General | OTC Pink

Last Closing

USD 21.14

Change

0.00 (0.00)%

Market Cap

USD 97.89B

Volume

270.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

GlaxoSmithKline PLC creates, discovers, develops, manufactures and markets pharmaceutical products including vaccines, over-the-counter (OTC) medicines and health-related consumer products.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-05 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZNCF AstraZeneca PLC

N/A

USD 240.18B
NVSEF Novartis AG

N/A

USD 208.10B
RHHBY Roche Holding Ltd ADR

N/A

USD 202.85B
RHHBF Roche Holding AG

N/A

USD 202.85B
RHHVF Roche Holding AG Participation

N/A

USD 202.50B
SNYNF Sanofi

N/A

USD 127.07B
DSNKY Daiichi Sankyo Co Ltd ADR

N/A

USD 66.43B
DSKYF Daiichi Sankyo Company Limited

N/A

USD 66.43B
CHGCF Chugai Pharmaceutical Co. Ltd

N/A

USD 53.36B
CHGCY Chugai Pharmaceutical Co Ltd A..

N/A

USD 52.77B

ETFs Containing GLAXF

DX2K:F Xtrackers - FTSE 100 Shor.. 0.00 % 0.00 %

N/A

USD 0.02B
DX2K:XETRA Xtrackers FTSE 100 Short .. 0.00 % 0.00 %

N/A

USD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 14.61% 94% A 73% C
Dividend Return 0.95% 36% F 23% F
Total Return 15.57% 94% A 73% C
Trailing 12 Months  
Capital Gain 13.05% 74% C 73% C
Dividend Return 3.76% 81% B- 50% F
Total Return 16.81% 75% C 73% C
Trailing 5 Years  
Capital Gain -16.28% 47% F 57% F
Dividend Return 19.87% 87% B+ 65% D
Total Return 3.60% 59% D- 63% D
Average Annual (5 Year Horizon)  
Capital Gain -5.67% 29% F 28% F
Dividend Return -1.26% 32% F 32% F
Total Return 4.42% 74% C 71% C-
Risk Return Profile  
Volatility (Standard Deviation) 20.30% 59% D- 86% B+
Risk Adjusted Return -6.19% 32% F 31% F
Market Capitalization 97.89B 83% B 99% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector